MCID: URN010
MIFTS: 53

Urinary Tract Obstruction

Categories: Nephrological diseases

Aliases & Classifications for Urinary Tract Obstruction

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 14 69
Obstructive Uropathy 12 52
Urinary Obstruction 12
Urologic Diseases 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5200
ICD10 33 N13.9
ICD9CM 35 599.6 599.60
NCIt 47 C3675 C79805
UMLS 69 C0178879

Summaries for Urinary Tract Obstruction

MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to glycogen storage disease due to lactate dehydrogenase deficiency and spastic monoplegia, and has symptoms including dysuria, polyuria and pain in urethra. An important gene associated with Urinary Tract Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and p70S6K Signaling. The drugs Fentanyl and Levobupivacaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 72 Urinary tract obstruction is a urologic disease consisting of a decrease in the free passage of urine... more...

Related Diseases for Urinary Tract Obstruction

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 glycogen storage disease due to lactate dehydrogenase deficiency 10.7 EGF PIK3CA
2 spastic monoplegia 10.6 ALB CCL2 NAGLU
3 cataract 25 10.6 ALB B2M
4 uterine corpus dissecting leiomyoma 10.6 EGF HBEGF UMOD
5 episodic ataxia 10.6 NAGLU TGFB1 UMOD
6 exocrine pancreatic insufficiency 10.6 ALB TGFB1 UMOD
7 allergic bronchopulmonary aspergillosis 10.6 ALB CCL2 KLK3
8 wernicke-korsakoff syndrome 10.5 ALB REN
9 astrocytoma 10.5 ALB B2M NAGLU
10 hypogonadotropic hypogonadism 10.5 B2M PTGS2
11 choroiditis 10.4 ALB CCL2 NAGLU UMOD
12 gallbladder cancer 10.4 ALB PIK3CA PTGS2
13 scabies 10.4 ALB B2M CCL2
14 iga glomerulonephritis 10.4 ALB REN
15 cystinosis 10.4 ALB REN UMOD
16 atrial septal defect 7, with or without av conduction defects 10.4 GGT1 REN
17 detrusor sphincter dyssynergia 10.4 CCL2 SMAD2 TGFB1
18 non-congenital cyst of kidney 10.3 ALB B2M REN
19 silver-russell syndrome due to 11p15 microduplication 10.3 NAGLU REN SLPI
20 survival motor neuron spinal muscular atrophy 10.3 ALB CCL2 REN
21 paranasal sinus sarcoma 10.3 ALB GGT1 REN
22 idiopathic juvenile osteoporosis 10.3 ALB B2M NAGLU UMOD
23 malignant struma ovarii 10.3 AQP2 PTGS2 TGFB1
24 urticaria 10.3 SMAD2 SMAD3 TGFB1
25 neovascular glaucoma 10.3 CCL2 EGF HBEGF PTGS2 UMOD
26 congenital methemoglobinemia 10.3 SMAD2 SMAD3 TGFB1
27 keratopathy 10.3 SMAD2 SMAD3 TGFB1
28 prostate neuroendocrine neoplasm 10.3 ALB NAGLU REN TGFB1
29 hereditary hemorrhagic telangiectasia 10.3 ALB GGT1 PIK3CA TGFB1
30 hypertrichosis of eyelid 10.3 CCL2 CTGF TGFB1
31 screw worm infectious disease 10.3 ALB CTGF TGFB1
32 exudative vitreoretinopathy 1 10.2 CCL2 CTGF TGFB1
33 tuberculum sellae meningioma 10.2 ALB GGT1 PTGS2
34 middle lobe syndrome 10.2 CCL2 CTGF TGFB1
35 familial periodic paralysis 10.2 B2M KLK3
36 patent foramen ovale 10.2 ALB CTGF TGFB1
37 nail disorder, nonsyndromic congenital, 1 10.2 EGF KLK3 PTGS2
38 idiopathic steroid-sensitive nephrotic syndrome with diffuse mesangial proliferation 10.2 CTGF SMAD2
39 acute liver failure 10.1 ALB B2M EGF REN
40 myopia 10.1 ALB AQP2 REN
41 cholangiolocellular carcinoma 10.1 KLK3 REN
42 sarcomatoid renal cell carcinoma 10.1 KLK3 SMAD2 SMAD3
43 atrophic vulva 10.1 ALB PKDREJ TGFB1
44 alternating exotropia 10.1 CCL2 EGF PKDREJ
45 retinitis pigmentosa 17 10.1 ALB CTGF NAGLU TGFB1
46 chronic myelomonocytic leukemia 10.1 ALB B2M REN UMOD
47 rheumatic myocarditis 10.0 CTGF SMAD3 TGFB1
48 posterior mediastinum cancer 9.9 KLK3 PKDREJ
49 renal oncocytoma 9.8 CCL2 CTGF SMAD3 TGFB1
50 carotid artery thrombosis 9.8 AQP2 REN

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 21)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hydronephrosis
Kidney Disease Nephrolithiasis, Type I
Paralytic Ileus Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Prostatitis Protein-Energy Malnutrition
Ureterolithiasis Urethral Stricture
Urinary Bladder Cancer

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction

Symptoms & Phenotypes for Urinary Tract Obstruction

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, pain in urethra, renal colic, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, uti symptoms, bladder discomfort, renal pain, other and unspecified genitourinary symptoms, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.37 AQP2 B2M CTGF EGF GGT1 HBEGF
2 homeostasis/metabolism MP:0005376 10.35 ALB AQP2 B2M CTGF GGT1 HBEGF
3 behavior/neurological MP:0005386 10.33 AQP2 GGT1 HBEGF NAGLU PIK3CA PTGS2
4 immune system MP:0005387 10.3 B2M CCL2 EGF GGT1 NAGLU PIK3CA
5 cardiovascular system MP:0005385 10.28 B2M CTGF HBEGF NAGLU PIK3CA PTGS2
6 mortality/aging MP:0010768 10.24 CTGF GGT1 HBEGF NAGLU PIK3CA PTGS2
7 endocrine/exocrine gland MP:0005379 10.21 TGFB1 PTGS2 SLC5A6 SMAD2 SMAD3 ALB
8 integument MP:0010771 10.21 NAGLU PIK3CA PTGS2 SMAD2 SMAD3 TGFB1
9 digestive/alimentary MP:0005381 10.18 ALB B2M CTGF EGF PTGS2 SLC5A6
10 liver/biliary system MP:0005370 10.01 ALB B2M NAGLU PTGS2 SLC5A6 SMAD2
11 renal/urinary system MP:0005367 9.96 TGFB1 UMOD ALB AQP2 GGT1 NAGLU
12 reproductive system MP:0005389 9.9 AQP2 B2M EGF GGT1 PIK3CA PKDREJ
13 neoplasm MP:0002006 9.87 TGFB1 ALB B2M PIK3CA PTGS2 SMAD2
14 skeleton MP:0005390 9.7 CTGF GGT1 HBEGF NAGLU PIK3CA PTGS2
15 vision/eye MP:0005391 9.28 SMAD2 SMAD3 TGFB1 CTGF EGF GGT1

Drugs & Therapeutics for Urinary Tract Obstruction

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
2
Levobupivacaine Approved Phase 4 27262-47-1 92253
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Alfuzosin Approved, Investigational Phase 4,Phase 3 81403-80-7 2092
6
Doxazosin Approved Phase 4 74191-85-8 3157
7
Dutasteride Approved, Investigational Phase 4,Phase 3 164656-23-9 152945 6918296
8
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
9
Fosfomycin Approved Phase 4 23155-02-4 446987
10
Sulfamethoxazole Approved Phase 4 723-46-6 5329
11
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13
Silodosin Approved Phase 4 160970-54-7
14 Mirabegron Approved Phase 4,Phase 2 223673-61-8
15
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2 106133-20-4 129211
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Baclofen Approved Phase 4 1134-47-0 2284
18
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
21 Adjuvants, Anesthesia Phase 4
22 Analgesics Phase 4,Phase 3
23 Analgesics, Opioid Phase 4
24 Anesthetics Phase 4,Phase 2,Phase 1
25 Anesthetics, General Phase 4
26 Anesthetics, Intravenous Phase 4
27 Anesthetics, Local Phase 4,Phase 2
28 Anti-Anxiety Agents Phase 4
29 Anti-Arrhythmia Agents Phase 4,Phase 2
30 Central Nervous System Depressants Phase 4,Phase 2
31 Diuretics, Potassium Sparing Phase 4,Phase 2
32 GABA Agents Phase 4
33 GABA Modulators Phase 4
34 Hypnotics and Sedatives Phase 4
35 Narcotics Phase 4
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
37 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
38 Psychotropic Drugs Phase 4
39 Sodium Channel Blockers Phase 4,Phase 2
40 Tranquilizing Agents Phase 4
41 Hormone Antagonists Phase 4,Phase 3,Phase 2
42 Hormones Phase 4,Phase 3,Phase 2
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2
46 Analgesics, Non-Narcotic Phase 4,Phase 3
47 Adrenergic Agents Phase 4,Phase 3,Phase 2
48 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2
49 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
50 Adrenergic Antagonists Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 77)

id Name Status NCT ID Phase Drugs
1 Quadratus Lumborum Block for Percutaneous Nephrostomy Unknown status NCT02121951 Phase 4 MAC
2 Functional MR Urography Completed NCT00301470 Phase 4
3 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients Completed NCT00696761 Phase 4 alfuzosin;alfuzosin;alfuzosin;alfuzosin
4 Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 Completed NCT01661621 Phase 4 Detrusitol 4 mg QD;Doxazosin 4 mg QD
5 Evaluation of Symptom-specific Goal Achievement Completed NCT00836823 Phase 4 Alfuzosin
6 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4 Dutasteride
7 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
8 Analgesic Efficacy of Ultrasound Guided Quadratus Lumborum Block During ESWL Completed NCT03080363 Phase 4 Bupivacaine;Lidocaine
9 Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation Completed NCT01820897 Phase 4 Fosfomycin-Trometamol;Sulfamethoxazole trimethoprim
10 Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Bladder Function Completed NCT02414373 Phase 4 Ropivacaine 2mg/ml;Bupivacaine
11 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4 Silodosin;Placebo
12 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Recruiting NCT02095665 Phase 4 Mirabegron;Tamsulosin;Tylenol #3
13 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate Recruiting NCT02749604 Phase 4
14 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Active, not recruiting NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
15 Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen Terminated NCT01003249 Phase 4 Baclofen;Placebo Comparator: Placebo
16 Tetra-NIRS Clinical Study Terminated NCT00871975 Phase 4
17 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
18 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
19 Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic Unknown status NCT01742689 Phase 3 Desmopressin intranasal spray;Placebo intranasal spray;Indomethacin suppository
20 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3 Omexel;spasfon
21 Transobturator Subtrigonal Tape vs Transobturator Suburethral Tape for Stress Urinary Incontinence Recruiting NCT02112591 Phase 3
22 Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients Active, not recruiting NCT02729116 Phase 2, Phase 3 Sitafloxacin;Ertapenem
23 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
24 Use of Alfuzosin in Stone Treatment With ESWL Withdrawn NCT00388271 Phase 3 Alfuzosin (Xatral);standard treatment
25 Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
26 Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction Completed NCT00507455 Phase 2 solifenacin succinate;tamsulosin hydrochloride;Placebo to solifenacin;Placebo to tamsulosin
27 A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Completed NCT00410514 Phase 2 Mirabegron;Placebo
28 Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms Completed NCT02244281 Phase 2 tamsulosin hydrochloride;Placebo
29 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
30 Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms Completed NCT00408954 Phase 2 UK-369,003;UK-369,003
31 Safety And Efficacy Of Solifenacin In Men With Overactive Bladder (OAB) And Detrusor Underactivity Completed NCT00441428 Phase 2 solifenacin
32 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
33 Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia Recruiting NCT02639442 Phase 1, Phase 2
34 Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Not yet recruiting NCT01552824 Phase 2
35 Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria Unknown status NCT02139059
36 Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase Unknown status NCT00628615
37 Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy Catheters Unknown status NCT00702286
38 A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney Unknown status NCT00739284
39 Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to BPH Under Tamsulosin Treatment Completed NCT03280420
40 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877
41 Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage Completed NCT02055430
42 Impact of 80 W KTP Laser Vaporization Prostatectomy on Severity of Obstruction in Benign Prostatic Hyperplasia Completed NCT00908427
43 The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction Completed NCT01482676
44 The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects Completed NCT00710749
45 Effects of Thoracic Epidural Anesthesia on Lower Urinary Tract Function Completed NCT00790231
46 Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study Completed NCT01220362 Bupivacain 0.125%;Bupivacain 0.125%/Fentanyl 2mcg/ml
47 Retrospective Review a Comprehensive Case Database of HoLEP Procedure Performed by a Single Surgeon Completed NCT01604148
48 Study to Look for Artifact on Computed Tomography (CT) Representing Kidney Stones Completed NCT01187745
49 Hydronephrosis ARFI Study Completed NCT01781845
50 Sonographic Measurement of Bladder Wall Thickness in Patients With Neurogenic Bladder Dysfunction Completed NCT01299792

Search NIH Clinical Center for Urinary Tract Obstruction

Genetic Tests for Urinary Tract Obstruction

Anatomical Context for Urinary Tract Obstruction

MalaCards organs/tissues related to Urinary Tract Obstruction:

39
Prostate, Kidney, Bone, Testes, Lung, Smooth Muscle, Neutrophil

Publications for Urinary Tract Obstruction

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 341)
id Title Authors Year
1
Complete upper urinary tract obstruction caused by penetrating pellet injury of the ureterintroduction. ( 28513528 )
2017
2
Ultrasound guided balloon catheterisation: a new method of fetal lower urinary tract obstruction management. ( 28580571 )
2017
3
Forkhead box O3 (FoxO3) regulates kidney tubular autophagy following urinary tract obstruction. ( 28705935 )
2017
4
Influence of bladder fullness on the detection of urinary tract obstruction by dynamic renal scintigraphy. ( 28894331 )
2017
5
Lower urinary tract obstruction: fetal intervention based on prenatal staging. ( 28730376 )
2017
6
Natural History of Fetal Lower Urinary Tract Obstruction with Normal Amniotic Fluid Volume at Initial Diagnosis. ( 28700992 )
2017
7
Analysis of Preoperative Urinary Tract Obstruction in Patients with Scoliosis. ( 27507671 )
2016
8
Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies. ( 27287190 )
2016
9
Vesico-amniotic shunting for lower urinary tract obstruction in a fetus with VACTERL association. ( 27061706 )
2016
10
Fetal Serum I^2-Microglobulin and Postnatal Renal Function in Lower Urinary Tract Obstruction Treated with Vesicoamniotic Shunt. ( 27603215 )
2016
11
Anterior Urethral Valve: A Rare But an Important Cause of Infravesical Urinary Tract Obstruction. ( 27231492 )
2016
12
Are ultrasound renal aspects associated with urinary biochemistry in fetuses with lower urinary tract obstruction? ( 27862070 )
2016
13
Sequential fetal serum I^2-microglobulin to predict postnatal renal function in bilateral or low urinary tract obstruction. ( 27197901 )
2016
14
Effectiveness of vesico-amniotic shunt in fetuses with congenital lower urinary tract obstruction: An updated systematic review and meta-analysis. ( 27270578 )
2016
15
Lower urinary tract obstruction in male children - a report of three cases. ( 27622420 )
2016
16
Urinary tract obstruction: Stem cells hinder stricture formation. ( 27349369 )
2016
17
EP21.11: Prediction of shunt dislodgement in fetuses with lower urinary tract obstruction. ( 27646514 )
2016
18
Urinary tract obstruction: NLRP3 inhibition prevents BOO. ( 26754189 )
2016
19
Factors associated with fetal shunt dislodgement in lower urinary tract obstruction. ( 27247093 )
2016
20
Two-year outcomes after diagnostic and therapeutic fetal cystoscopy for lower urinary tract obstruction. ( 26739350 )
2016
21
Congenital urinary tract obstruction: the long view. ( 26088076 )
2015
22
Current applications of in utero intervention for lower urinary tract obstruction. ( 26441047 )
2015
23
Re: Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting. R. Ruano, N. Sananes, H. Sangi-Haghpeykar, S. Hernandez-Ruano, R. Moog, F. Becmeur, A. Zaloszyc, A. M. Giron, B. Morin and R. Favre. Ultrasound Obstet Gynecol 2015; 45: 452-458. ( 25833370 )
2015
24
Postobstructive diuresis in cats with naturally occurring lower urinary tract obstruction: incidence, severity and association with laboratory parameters on admission. ( 26179575 )
2015
25
Fetal Lower Urinary Tract Obstruction (LUTO): a practical review for providers. ( 27057343 )
2015
26
Defining and predicting 'intrauterine fetal renal failure' in congenital lower urinary tract obstruction. ( 26525197 )
2015
27
Fetal Lower Urinary Tract Obstruction - A proposal of Standardized Multidisciplinary Prenatal Management based on Disease Severity. ( 26690832 )
2015
28
Outcome in fetal lower urinary tract obstruction: a prospective registry. ( 25689128 )
2015
29
Palliative management of malignant upper urinary tract obstruction. ( 26052193 )
2014
30
Fetal urine biochemistry at 13-23 weeks in low urinary tract obstruction: criteria for in utero treatment. ( 25412852 )
2014
31
Lower urinary tract obstruction in the fetus and neonate. ( 25155733 )
2014
32
Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesico-amniotic shunting. ( 25157756 )
2014
33
Pathological feature and immunoprofile of cystitis glandularis accompanied with upper urinary tract obstruction. ( 25136635 )
2014
34
Evaluation of the Cost Effectiveness of Vesico-Amniotic Shunting in the Management of Congenital Lower Urinary Tract Obstruction (Based on Data from the PLUTO Trial). ( 24376546 )
2013
35
Outcomes of fetuses with lower urinary tract obstruction treated with vesicoamniotic shunt: a single-institution experience. ( 23701767 )
2013
36
Laparoscopic ureterocalicostomy for complicated upper urinary tract obstruction: mid-term follow-up. ( 24217801 )
2013
37
Urinary tract obstruction in the mouse: the kinetics of distal nephron injury. ( 23917879 )
2013
38
Postmortem high-resolution fetal magnetic resonance imaging in three cases of lower urinary tract obstruction. ( 23752166 )
2013
39
Epidermal growth factor and monocyte chemotactic peptide-1: potential biomarkers of urinary tract obstruction in children with hydronephrosis. ( 23228281 )
2013
40
The experience of pregnant women with a diagnosis of fetal lower urinary tract obstruction (LUTO). ( 24290423 )
2013
41
Effects of tolterodine and trospium chloride on renal damage induced by partial upper urinary tract obstruction. ( 23453648 )
2013
42
Prenatal cytogenetic diagnosis from fetal urine in lower urinary tract obstruction. ( 23751043 )
2013
43
PI3K mediates stretch-induced COX-2 expression during urinary tract obstruction. ( 22998445 )
2013
44
Monosodium glutamate (MSG) consumption is associated with urolithiasis and urinary tract obstruction in rats. ( 24086562 )
2013
45
Erdheim-Chester disease: an uncommon cause of upper urinary tract obstruction. ( 24088590 )
2013
46
Microtomographic analysis of lower urinary tract obstruction. ( 23977847 )
2013
47
Fetal lower urinary tract obstruction and its management. ( 23138754 )
2013
48
A rare case of paediatric pelvic ring injury with lower urinary tract obstruction secondary to a combat blast mechanism. ( 23746855 )
2013
49
The Percutaneous shunting in Lower Urinary Tract Obstruction (PLUTO) study and randomised controlled trial: evaluation of the effectiveness, cost-effectiveness and acceptability of percutaneous vesicoamniotic shunting for lower urinary tract obstruction. ( 24331029 )
2013
50
Clinical character of cystitis glandularis accompanied with upper urinary tract obstruction. ( 24282462 )
2013

Variations for Urinary Tract Obstruction

Expression for Urinary Tract Obstruction

Search GEO for disease gene expression data for Urinary Tract Obstruction.

Pathways for Urinary Tract Obstruction

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 30)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.28 B2M CCL2 EGF HBEGF PIK3CA PTGS2
2
Show member pathways
12.96 CCL2 CTGF EGF HBEGF PTGS2 REN
3
Show member pathways
12.79 CCL2 PIK3CA SMAD2 SMAD3 TGFB1
4 12.4 EGF KLK3 PIK3CA PTGS2 SMAD2 SMAD3
5 12.33 PIK3CA SMAD2 SMAD3 TGFB1
6 12.19 HBEGF PIK3CA SMAD2 TGFB1
7 12.07 EGF PTGS2 SMAD2 SMAD3 TGFB1
8 12.06 CTGF SMAD2 SMAD3 TGFB1
9 12.02 GGT1 HBEGF SLC5A6 TGFB1
10
Show member pathways
11.86 EGF PIK3CA SMAD2 SMAD3 TGFB1
11 11.82 SMAD2 SMAD3 TGFB1
12
Show member pathways
11.82 SMAD2 SMAD3 TGFB1
13 11.8 EGF HBEGF TGFB1
14
Show member pathways
11.78 SMAD2 SMAD3 TGFB1
15 11.74 CCL2 PTGS2 REN TGFB1
16 11.72 SMAD2 SMAD3 TGFB1
17 11.64 SMAD2 SMAD3 TGFB1
18
Show member pathways
11.62 SMAD2 SMAD3 TGFB1
19
Show member pathways
11.6 EGF HBEGF KLK3 PIK3CA SMAD3 TGFB1
20 11.59 EGF SMAD3 TGFB1
21 11.55 CCL2 PIK3CA SMAD2 SMAD3 TGFB1
22 11.53 CCL2 CTGF EGF TGFB1
23 11.47 EGF SMAD2 SMAD3 TGFB1
24 11.46 PTGS2 SMAD3 TGFB1
25 11.38 CTGF SMAD2 SMAD3 TGFB1
26 11.2 SMAD2 SMAD3 TGFB1
27 11.1 CTGF SMAD2 SMAD3
28 11.08 CCL2 HBEGF PIK3CA
29 10.91 SMAD2 SMAD3 TGFB1
30
Show member pathways
10.79 EGF HBEGF PIK3CA SMAD2 SMAD3 TGFB1

GO Terms for Urinary Tract Obstruction

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ALB B2M CCL2 CTGF EGF HBEGF
2 platelet alpha granule lumen GO:0031093 9.43 ALB EGF TGFB1
3 extracellular space GO:0005615 9.36 ALB B2M CCL2 CTGF EGF GGT1
4 SMAD protein complex GO:0071141 9.32 SMAD2 SMAD3
5 SMAD2-SMAD3 protein complex GO:0071144 9.16 SMAD2 SMAD3

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.99 CCL2 EGF HBEGF TGFB1
2 response to drug GO:0042493 9.93 B2M CCL2 PTGS2 REN TGFB1
3 response to lipopolysaccharide GO:0032496 9.91 CCL2 PTGS2 REN SLPI
4 aging GO:0007568 9.88 CCL2 CTGF PTGS2 TGFB1
5 response to organic substance GO:0010033 9.86 PTGS2 REN TGFB1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 EGF HBEGF TGFB1
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 PIK3CA PTGS2 TGFB1
8 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.83 EGF HBEGF PIK3CA
9 response to wounding GO:0009611 9.83 CCL2 CTGF TGFB1
10 response to glucose GO:0009749 9.82 CTGF SMAD2 TGFB1
11 angiogenesis GO:0001525 9.8 CCL2 CTGF EGF PIK3CA PTGS2
12 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.79 SMAD2 SMAD3 TGFB1
13 SMAD protein signal transduction GO:0060395 9.77 SMAD2 SMAD3 TGFB1
14 positive regulation of epithelial to mesenchymal transition GO:0010718 9.73 SMAD2 SMAD3 TGFB1
15 ureteric bud development GO:0001657 9.72 SMAD2 SMAD3 TGFB1
16 ERBB2 signaling pathway GO:0038128 9.69 EGF HBEGF PIK3CA
17 wound healing GO:0042060 9.68 SMAD3 TGFB1
18 negative regulation of ERBB signaling pathway GO:1901185 9.68 EGF HBEGF
19 lens fiber cell differentiation GO:0070306 9.67 SMAD3 TGFB1
20 cellular response to ATP GO:0071318 9.67 CCL2 PTGS2
21 protein kinase B signaling GO:0043491 9.67 CCL2 PIK3CA TGFB1
22 positive regulation of catenin import into nucleus GO:0035413 9.65 EGF SMAD3
23 endoderm development GO:0007492 9.65 SMAD2 SMAD3 TGFB1
24 cell chemotaxis GO:0060326 9.64 CCL2 HBEGF
25 primary miRNA processing GO:0031053 9.64 SMAD2 SMAD3
26 pericardium development GO:0060039 9.63 SMAD2 SMAD3
27 response to cholesterol GO:0070723 9.63 SMAD2 TGFB1
28 embryonic foregut morphogenesis GO:0048617 9.62 SMAD2 SMAD3
29 transforming growth factor beta receptor signaling pathway GO:0007179 9.62 CCL2 SMAD2 SMAD3 TGFB1
30 nodal signaling pathway GO:0038092 9.59 SMAD2 SMAD3
31 common-partner SMAD protein phosphorylation GO:0007182 9.58 SMAD2 TGFB1
32 regulation of striated muscle tissue development GO:0016202 9.57 SMAD3 TGFB1
33 positive regulation of collagen biosynthetic process GO:0032967 9.54 CCL2 CTGF TGFB1
34 positive regulation of extracellular matrix assembly GO:1901203 9.52 SMAD3 TGFB1
35 paraxial mesoderm morphogenesis GO:0048340 9.46 SMAD2 SMAD3
36 epidermal growth factor receptor signaling pathway GO:0007173 9.46 EGF HBEGF PIK3CA TGFB1
37 evasion or tolerance of host defenses by virus GO:0019049 9.43 SMAD3 TGFB1
38 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.43 SMAD2 SMAD3 TGFB1
39 SMAD protein complex assembly GO:0007183 9.13 SMAD2 SMAD3 TGFB1
40 regulation of binding GO:0051098 8.8 SMAD2 SMAD3 TGFB1
41 positive regulation of cell proliferation GO:0008284 10.07 CTGF EGF HBEGF PTGS2 TGFB1
42 negative regulation of cell proliferation GO:0008285 10.02 PTGS2 SMAD2 SMAD3 TGFB1 UMOD

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGF HBEGF PIK3CA
2 growth factor activity GO:0008083 9.46 CTGF EGF HBEGF TGFB1
3 co-SMAD binding GO:0070410 9.4 SMAD2 SMAD3
4 type I transforming growth factor beta receptor binding GO:0034713 9.37 SMAD2 TGFB1
5 primary miRNA binding GO:0070878 9.26 SMAD2 SMAD3
6 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 8.96 SMAD2 SMAD3
7 transforming growth factor beta receptor binding GO:0005160 8.8 SMAD2 SMAD3 TGFB1

Sources for Urinary Tract Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....